Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MBOT Stock Forecast 2026-2027
$1.84
Current Price
$123.58M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MBOT Price Targets
+552.2%
To High Target of $12.00
+171.7%
To Median Target of $5.00
+117.4%
To Low Target of $4.00
MBOT Price Momentum
-9.4%
1 Week Change
-16.0%
1 Month Change
-34.5%
1 Year Change
-8.0%
Year-to-Date Change
-60.6%
From 52W High of $4.67
+15.0%
From 52W Low of $1.60
📊 TOP ANALYST CALLS
Did MBOT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Microbot is one of their latest high-conviction picks.
Latest MBOT Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, MBOT has a bullish consensus with a median price target of $5.00 (ranging from $4.00 to $12.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $1.84, the median forecast implies a 171.7% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 552.2% upside. Conversely, the most conservative target is provided by Alex Nowark at LUCID CAPITAL MARKETS, suggesting a 117.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MBOT Analyst Ratings
3
Buy
0
Hold
0
Sell
MBOT Price Target Range
Low
$4.00
Average
$5.00
High
$12.00
Current: $1.84
Latest MBOT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MBOT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 3, 2026 | LUCID CAPITAL MARKETS | Alex Nowark | Buy | Initiates | $4.00 |
| Apr 14, 2026 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $12.00 |
| Feb 10, 2026 | B. Riley Securities | Buy | Initiates | $N/A | |
| Dec 3, 2025 | Roth Capital | Buy | Initiates | $N/A | |
| Nov 28, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 15, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 11, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Apr 10, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 24, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jun 3, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 16, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Oct 18, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 26, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 6, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 9, 2023 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 25, 2020 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 25, 2020 | H.C. Wainwright | Buy | Reiterates | $N/A | |
| Nov 25, 2020 | Ladenburg Thalmann | Neutral | Downgrade | $N/A | |
| Aug 18, 2020 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jan 13, 2020 | H.C. Wainwright | Buy | Reiterates | $N/A |
Microbot Medical Inc. (MBOT) Competitors
The following stocks are similar to Microbot based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MBOT
Microbot Medical
mkt cap
136.34M
Microbot Medical Inc. (MBOT) Financial Data
Microbot Medical Inc. has a market capitalization of $123.58M with a P/E ratio of -6.4x. The company generates $105,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -4,114.3% and return on equity of -27.6%.
Valuation Metrics
Market Cap
$123.58M
Enterprise Value
$60.04M
P/E Ratio
-6.4x
PEG Ratio
0.2x
Price/Sales
1,253.7x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
+1.9%
Operating Margin
-4,114.3%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+58.6%
Current Ratio
22.6x
Debt/Equity
1.2x
ROE
-27.6%
ROA
-18.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Microbot Medical Inc. (MBOT) Business Model
About Microbot Medical Inc.
What They Do
Develops innovative micro-robotic medical solutions.
Business Model
Microbot Medical Inc. generates revenue by creating advanced medical devices that enhance minimally invasive surgeries and medical procedures. Their products focus on improving precision and efficacy in healthcare, catering to the increasing demand for less invasive treatment options.
Additional Information
Headquartered in Massachusetts, the company is at the forefront of robotic technology for endoluminal procedures, significantly impacting the medical device market. As healthcare providers seek to leverage technological advancements to improve patient outcomes, Microbot Medical Inc. is positioned as a key player in transforming surgical practices.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
20
CEO
Mr. Harel Gadot
Country
United States
IPO Year
1992
Website
microbotmedical.comMicrobot Medical Inc. (MBOT) Latest News & Analysis
Latest News
Quick Summary
Microbot Medical Inc. (Nasdaq: MBOT) has acquired its first North Carolina customer for the LIBERTY® Endovascular Robotic System, expanding its presence across the U.S. healthcare market.
Why It Matters
Microbot Medical's expansion into North Carolina signifies growing acceptance of the LIBERTY System, potentially boosting revenue and market share in a competitive healthcare sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Microbot Medical Inc. has received marketing clearance for its LIBERTY Endovascular Robotic System in Israel, marking it as the first country outside the U.S. to do so, facilitating further commercial opportunities.
Why It Matters
The approval in Israel expands Microbot Medical's market potential for the LIBERTY System, potentially increasing revenue and investor confidence in the company's growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Microbot Medical Inc. (MBOT) held a shareholder and analyst call, discussing company performance and future plans. Specific details on financials or strategies were not provided in the excerpt.
Why It Matters
The Microbot Medical analyst call may provide insights on financial performance, product development, and future strategies, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
After Plunging 22.6% in 4 Weeks, Here's Why the Trend Might Reverse for Microbot Medical (MBOT)
18 days ago
Quick Summary
Microbot Medical (MBOT) is in oversold territory, suggesting selling pressure may be easing. Analyst consensus on raising earnings estimates could indicate a potential trend reversal.
Why It Matters
Microbot Medical (MBOT) may be due for a rebound after heavy selling and positive analyst sentiment on earnings, indicating a potential buying opportunity for investors.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Microbot will hold a conference call to discuss recent progress, featuring its executive team and current LIBERTY users, Dr. Charles Briggs and Dr. Zachary Bercu.
Why It Matters
The conference call indicates transparency and engagement from Microbot, potentially boosting investor confidence. Insights from current users may highlight product effectiveness and market potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Microbot Medical Inc. reported Q2 revenue exceeding Q1, driven by the Full Market Release of the LIBERTY System and increased customer orders and new accounts.
Why It Matters
Increased revenue from the LIBERTY System's transition to Full Market Release and growing customer orders indicate strong market demand, enhancing Microbot Medical's growth outlook and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MBOT Stock
What is Microbot Medical Inc.'s (MBOT) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Microbot Medical Inc. (MBOT) has a median price target of $5.00. The highest price target is $12.00 and the lowest is $4.00.
Is MBOT stock a good investment in 2026?
According to current analyst ratings, MBOT has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.84. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MBOT stock?
Wall Street analysts predict MBOT stock could reach $5.00 in the next 12 months. This represents a 171.7% increase from the current price of $1.84. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Microbot Medical Inc.'s business model?
Microbot Medical Inc. generates revenue by creating advanced medical devices that enhance minimally invasive surgeries and medical procedures. Their products focus on improving precision and efficacy in healthcare, catering to the increasing demand for less invasive treatment options.
What is the highest forecasted price for MBOT Microbot Medical Inc.?
The highest price target for MBOT is $12.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 552.2% increase from the current price of $1.84.
What is the lowest forecasted price for MBOT Microbot Medical Inc.?
The lowest price target for MBOT is $4.00 from Alex Nowark at LUCID CAPITAL MARKETS, which represents a 117.4% increase from the current price of $1.84.
What is the overall MBOT consensus from analysts for Microbot Medical Inc.?
The overall analyst consensus for MBOT is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are MBOT stock price projections?
Stock price projections, including those for Microbot Medical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 8:00 AM UTC